PT-141 Effects: Benefits Measured, Side Effects Logged

The short version

PT-141 effects come in two flavors: what controlled studies measured, and what people online report. They are not the same thing, and this page keeps them apart.

The measured benefit: in approved use (low sexual desire causing distress in premenopausal women), desire goes up a little and distress goes down a little versus a dummy injection ^[3]. "A little" is honest — the effect is statistically real but small, and some researchers question how meaningful it is ^[3].

The measured downside: nausea, often. Around 40% of women in long-term use felt it ^[4]. Flushing and headache are next ^[4]. Repeated frequent dosing can darken skin and gums ^[7]. The label warns about a short-lived blood-pressure rise ^[7].

Nothing here is a dose recommendation.

What the studies measured

In the pivotal RECONNECT trials (n=1267 premenopausal women with HSDD), bremelanotide 1.75 mg as-needed raised the desire score (FSFI-desire +0.35, P<.001) and lowered desire-related distress (FSDS-DAO item 13 -0.33, P<.001) over 24 weeks versus placebo ^[3]. Both coprimary endpoints met. Both effect sizes small.

The 52-week open-label extension (684 women) showed no new safety signals and sustained desire improvement ^[4]. Tolerability, not efficacy, was the limiting factor.

A 2022 fMRI study (31 women) gave mechanistic backing: MC4R agonism increased desire for up to 24 hours and changed how the brain processed erotic stimuli ^[5]. A 2026 systematic review and meta-analysis pooled the trials and found bremelanotide improved total FSFI plus the desire and arousal subscales ^[15].

PT-141 for men

Off-label and investigational — state it plainly. PT-141 is not FDA-approved for men ^[7]. The male evidence is early-phase: systemic administration produced dose-dependent erectile activity in men with erectile dysfunction in dose-ranging work ^[1], and early intranasal studies reported a statistically significant erectile response above ~7 mg ^[7]. A 2025 narrative review positions PT-141 as a centrally acting investigational ED option and stresses that large trials are still needed ^[14]. One 2008 erectile-dysfunction salvage study carries a 2023 Expression of Concern and should be treated as disputed ^[7].

PT-141 for women

This is the one approved column. Bremelanotide is indicated for acquired, generalized HSDD in premenopausal women ^[7][10]. That is the population the Phase 3 trials enrolled and the only population the FDA cleared ^[3][7]. It is distinct from off-label transdermal testosterone used in postmenopausal women ^[10]. Postmenopausal use of PT-141 is not approved ^[7]. The benefit in the approved group is the modest desire/distress shift described above ^[3].

What people report

These are effects reported by the research-use community — anecdotal, not clinical evidence, and not verified by controlled trials. No doses are attached, and these reports do not establish that PT-141 does anything.

Reported upsides cluster around increased sexual desire and arousal appearing hours after a dose. Reported downsides echo the trial data closely: nausea is the most-mentioned complaint, sometimes strong enough to overshadow any benefit, alongside flushing, headache, and a flushed or "hot" feeling. Some report transient nausea fading with repeated exposure; others report it does not. None of that is a clinical finding — the controlled-trial profile above is the evidence.

PT-141 side effects

From the controlled record. Over long-term use the most common drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[4]. Nausea is the principal tolerability issue and a notable driver of discontinuation ^[4]. These are cited trial findings, not anecdotes.

Safety & cautions

Each caution below is cited.

Blood pressure. The label documents a transient blood-pressure increase and contraindicates use in uncontrolled hypertension or known cardiovascular disease ^[7]. This is a labeled warning, not a theoretical one.

Nausea. Common (~40% over long-term use) and a leading reason people stop ^[4].

Hyperpigmentation. Darkening of the face, gums, and breasts is reported with repeated frequent dosing, attributed to MC1R activation (a peripheral melanocortin receptor governing pigment) ^[7].

Appetite circuits. MC4R is also expressed in appetite circuits; caloric-intake and body-weight effects seen in high-frequency Phase 1 dosing are a relevant pharmacological consideration — theoretical for ordinary use, and not an approved indication ^[7].

Unregulated material. A "PT-141 research chemical" sits outside the approval framework, with no oversight of identity, purity, or concentration ^[7]. This page recommends no dose and is not medical advice.